CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica announced it will host a conference call on June 27, 2024, at 8:30 a.m. ET to discuss topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS). The clinical-stage biopharmaceutical company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. Interested parties can join the call via a live webcast or dial-in numbers provided on CalciMedica's investor relations website. A webcast replay will be available post-event.
- CalciMedica is progressing with the Phase 2b CARPO trial, indicating continued advancement in their pipeline.
- Hosting a conference call to discuss topline data highlights transparency and keeps investors informed.
- None.
Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m. PT
Conference Call and Webcast Details
Stockholders and other interested parties may participate in the call by following the instructions below. A live webcast of the event can also be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be available following the completion of the event.
Participant Webcast Link: https://app.webinar.net/jDbvg4E9yPn
- Click on the webcast link and complete the online registration form.
- Upon registering, you will be connected to the online webcast.
Participant Dial-in Numbers: 1-800-836-8184 (US) and 1-646-357-8785 (international)
- If prompted by the operator, ask to join the CalciMedica Phase 2b CARPO Topline Data Readout call.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has completed a Phase 2b trial (called CARPO – NCT04681066) in AP with SIRS and a Phase 2b trial (called CARDEA – NCT04345614) in COVID pneumonia patients, continues to support the ongoing Phase 1/2 AIPT study (called CRSPA – NCT04195347), with data expected in 2025, and has initiated its Phase 2 study (called KOURAGE – NCT06374797) in AKI with associated AHRF with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-host-conference-call-to-review-topline-data-from-phase-2b-carpo-trial-of-auxora-in-acute-pancreatitis-ap-302183691.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica hosting the conference call for the Phase 2b CARPO trial data?
What is the focus of CalciMedica's Phase 2b CARPO trial?
How can I join the CalciMedica conference call for the Phase 2b CARPO trial?
What is CalciMedica's stock symbol?
